Who was studied?
Mice bearing bilateral 4T1 breast tumors, with additional immune-cell depletion experiments.
What does the publication report?
PRaG suppressed growth at both sites. Depleting CD8+ T cells or cDC1 impaired tumor control; the increase in intratumoral CD8+ infiltration alone was not statistically significant.
Safety findings
No human safety conclusions can be drawn from these animal data.
How should we interpret it?
A preclinical conference abstract; mouse mechanisms require independent replication and human investigation.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
Antitumor effect of PRaG therapy in a triple-negative breast cancer model. · DOI: 10.1200/JCO.2025.43.16_suppl.e14604
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.